WO2022040110A3 - Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases - Google Patents

Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases Download PDF

Info

Publication number
WO2022040110A3
WO2022040110A3 PCT/US2021/046193 US2021046193W WO2022040110A3 WO 2022040110 A3 WO2022040110 A3 WO 2022040110A3 US 2021046193 W US2021046193 W US 2021046193W WO 2022040110 A3 WO2022040110 A3 WO 2022040110A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
treatment
alzheimer
fibrosis
nafld
Prior art date
Application number
PCT/US2021/046193
Other languages
French (fr)
Other versions
WO2022040110A2 (en
Inventor
Sheng Liu
Original Assignee
Sheng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sheng Liu filed Critical Sheng Liu
Publication of WO2022040110A2 publication Critical patent/WO2022040110A2/en
Publication of WO2022040110A3 publication Critical patent/WO2022040110A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application provides compositions and methods useful in the treatment of immune-related diseases, inflammation related diseases, Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), liver cirrhosis, Alzheimer's diseases, fibrosis diseases and Drug Induced Liver Injury (DILI). Additionally, this invention related to novel compositions and methods to screen drugs for the treatment of the diseases. The invention contemplates that methoxyamine (MOA), alone or with other drugs shall be used as a treatment for aldehyde and ketone related immune-related and inflammation diseases, NAFLD, NASH, liver cirrhosis, Alzheimer's diseases, fibrosis diseases and DILL Specifically, the invention contemplates that methoxyamine, alone or with other potential drugs in sequence or in combination, shall be used as a treatment for NAFLD, NASH and liver cirrhosis Alzheimer's diseases, fibrosis diseases, and the invention contemplates that methoxyamine with obeticholic acid in sequence or in combination, shall be used as a treatment for NAFLD, NASH and liver cirrhosis.
PCT/US2021/046193 2020-08-18 2021-08-17 Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases WO2022040110A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063067288P 2020-08-18 2020-08-18
US202063067225P 2020-08-18 2020-08-18
US202063067209P 2020-08-18 2020-08-18
US63/067,225 2020-08-18
US63/067,209 2020-08-18
US63/067,288 2020-08-18
US202063109843P 2020-11-04 2020-11-04
US63/109,843 2020-11-04

Publications (2)

Publication Number Publication Date
WO2022040110A2 WO2022040110A2 (en) 2022-02-24
WO2022040110A3 true WO2022040110A3 (en) 2022-03-31

Family

ID=80323195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/046193 WO2022040110A2 (en) 2020-08-18 2021-08-17 Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases

Country Status (1)

Country Link
WO (1) WO2022040110A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887472B (en) * 2022-10-28 2024-03-19 广州医科大学 Application of sodium mannite in preparation of medicines for treating pulmonary fibrosis diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103228A1 (en) * 1999-10-06 2002-08-01 Torrent Pharmaceuticals Ltd. Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
WO2017210147A1 (en) * 2016-05-29 2017-12-07 Wei Jia Liver disease-related biomarkers and methods of use thereof
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103228A1 (en) * 1999-10-06 2002-08-01 Torrent Pharmaceuticals Ltd. Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
WO2017210147A1 (en) * 2016-05-29 2017-12-07 Wei Jia Liver disease-related biomarkers and methods of use thereof
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURCHAM P.C., KERR P.G., FONTAINE F.: "The antihypertensive hydralazine is an efficient scavenger of acrolein", REDOX REPORT., CHURCHILL LIVINGSTONE, EDINBURGH., GB, vol. 5, no. 1, 1 February 2000 (2000-02-01), GB , pages 47 - 49, XP055921801, ISSN: 1351-0002, DOI: 10.1179/rer.2000.5.1.47 *
ELLIS, E.M.: "Reactive carbonyls and oxidative stress: Potential for therapeutic intervention", PHARMACOLOGY & THERAPEUTICS, ELSEVIER., GB, vol. 115, no. 1, 1 July 2007 (2007-07-01), GB , pages 13 - 24, XP022134151, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2007.03.015 *
HEIDARI REZA, NIKNAHAD HOSSEIN, JAMSHIDZADEH AKRAM, AZARPIRA NEGAR, BAZYARI MANDANA, NAJIBI ASMA: "Carbonyl Traps as Potential Protective Agents against Methimazole-Induced Liver Injury ", JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, WILEY, US, vol. 29, no. 4, 1 April 2015 (2015-04-01), US , pages 173 - 181, XP055921802, ISSN: 1095-6670, DOI: 10.1002/jbt.21682 *

Also Published As

Publication number Publication date
WO2022040110A2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
PH12021550423A1 (en) Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
EP2636404A3 (en) Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
MXPA05009933A (en) Compositions comprising fatty acids and amino acids.
WO2021195467A3 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
WO2012050925A3 (en) Highly soluble leptins
ATE521343T1 (en) COMPOSITIONS OF RASAGILIN THAT DISSOLVE IN THE MOUTH
MX2019005533A (en) Treatment for fibrosis.
WO2005009436A8 (en) Dispersible formulation of an anti-inflammatory agent
EP4234568A3 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
WO2022040110A3 (en) Alkylating agent and combinations in the treatment of immune-related and liver diseases, alzheimer's diseases and fibrosis diseases
CA3139615A1 (en) Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2017123592A8 (en) Bacteria engineered to treat disorders associated with bile salts
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
MX2023005550A (en) Dichlorophenol hsd17b13 inhibitors and uses thereof.
EP3781158A4 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
WO2007106909A3 (en) Method of using pomegranate extracts for increasing prostate specific antigen doubling time
FR3050112B1 (en) USE OF FENOFIBRIC ACID IN THE TREATMENT OF HEPATIC DISEASES
EP3718552A4 (en) Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis
WO2021041561A3 (en) Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
AR114739A1 (en) RNAi AGENTS TO INHIBIT THE EXPRESSION OF 17b-HSD TYPE 13 (HSD17B13), COMPOSITIONS OF SUCH AGENTS, AND METHODS OF USE
WO2019232415A8 (en) Bacteria engineered to treat liver disease
WO2022245981A3 (en) Use of microrna mimics to inhibit or treat liver disease
EA202190800A1 (en) RNA AGENTS FOR INHIBITING EXPRESSION 17beta-HSD TYPE 13 (HSD17B13), THEIR COMPOSITIONS AND METHODS OF APPLICATION
TW202426431A (en) Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21858917

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21858917

Country of ref document: EP

Kind code of ref document: A2